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11 ± 8 years, and 6 patients were men. Results of OH testing
obtained during all inpatient or outpatient visits between June
2016 and June 2018, after 3 minutes of standing, are shown in
the Figure, which graphically illustrates the diagnosis perfor-
mances of the different tests. Sensitivity, calculated individually
and averaged, was 93% for the ΔHR/ΔSBP ratio and 84% for
the 17bpm ΔHR. It was 77% for the usual 15bpm ΔHR
threshold.
Our external cohort of patients with pure autonomic fail-
ure, a rare disorder but the epitome of primary and isolated
peripheral autonomic failure, confirms the excellent sensitivity of
the recently published 0.492bpm/mmHg ΔHR/ΔSBP ratio to
detect neurogenic orthostatic hypotension. A cohort of patients
with non-neurogenic OH would be necessary to confirm its
specificity.
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Gender Inequities in the Multiple Sclerosis
Community: A Call for Action
International Women in MS
We thank Moneim and colleagues for calling attention to the
issue of gender inequality in MS clinical trial steering committees
and in authorship on publications emerging from phase 3 clinical
trials.1 Gender inequality is a long-standing problem in publica-
tion practices in general,2 as well as in neurology,3,4 academic
medicine,5 and science,6 so it is not surprising to see it reflected
in the field of multiple sclerosis (MS). This occurs despite the
availability of a substantial number of successful senior female
academic neurologists and neuroscientists worldwide who have
extensive experience in MS clinical and basic research methodol-
ogy; some are cosigners of this letter. Are there additional reasons
beyond those articulated by Moneim and colleagues to explain
why senior female neurologists are not approached to play lead
roles in MS clinical trial committees and more broadly, clinical
MS neurologists and MS researchers?
Moneim and colleagues observed that women have been
historically underrepresented as first and last authors on publi-
cations from phase 3 clinical trials in MS sponsored by phar-
maceutical companies, which tend to repeatedly choose a
select group of academicians to serve as authors.7 In addition,
eminent lead investigators have to some extent, consciously or
subconsciously, nurtured a closed group for clinical trial lead-
ership in which women are not well represented. Publication
practices may also be influenced by gender balance on journal
editorial boards. In an informal examination of chief and
section editors of 17 major journals that publish MS studies,
we found that median representation by women was 16.6%.
This is approximately half of the proportion of female faculty
in the 29 top-ranked US academic neurology programs
(30.8%).4 Gender imbalance also occurs in scientific programs
at professional meetings8 and in recognition awards,9 issues
that have been addressed with limited success by the American
Neurological Association, American Academy of Neurology,
and the American and European Committees for Treatment
and Research in MS.
Gender discrimination is costly, not only from a personal
career perspective, but because it excludes or delays important
contributions from skilled, talented individuals. This can affect
progress toward a better understanding of the pathogenesis and
treatment of neurological diseases, including MS.
Although it is disheartening to see continuing evidence of
the gender discrimination that permeates not only academic
medicine and science, but also society at large, we are encouraged
that there is interest in shedding greater light on the issue. We
believe that it is time for the MS community to work harder
toward achieving equal participation by all women at all levels.
To this end, we submit this letter as a call to action, and offer
the following recommendations:
1. Develop structured opportunities to foster greater
awareness of gender-based imbalances and existing
biases, including implicit or unconscious bias. This can
occur on a committee level in professional organiza-
tions and should include representatives from pharma-
ceutical companies. The primary goal would be to
establish task forces charged with gathering and analyz-
ing data on gender concerning:
a. Clinical trial leadership, including clinical trial
steering committees, data safety monitoring boards,
authorship committees, and other active committees.
b. Participation by physicians and basic scientists on
editorial boards and grant review panels and in scien-
tific programs, professional organizations, and academic
institutions, including neurology departments, as well
as in other relevant entities.
2. Establish specific goals toward achieving equal repre-
sentation by women at all levels in a timely fashion.
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a. Develop mechanisms to track and regularly review
progress toward these goals, with an ultimate goal of
achieving and maintaining gender parity.
b. Create mechanisms to report inequalities and
encourage continued efforts to raise awareness.
c. Develop mechanisms to recognize and celebrate
contributions from women.
d. Promote efforts to support and mentor women
(such as the International Women in MS, the Women
Leading in Neurology leadership program of the
American Academy of Neurology,3 and the Association
for Women in Science), especially for junior
investigators.
There are many models and transformative voices3,6,10–12
that can be tapped in efforts to swing the pendulum toward a
truly equal opportunity environment in the MS community. It
is clear that conscious, thoughtful, and persistent efforts by all
stakeholders, both men and women, are needed to implement
enduring change worthy of celebration. We look forward to par-
ticipating in an ongoing and collaborative dialogue toward
achieving this important goal.
This letter was authored by Emmanuelle Waubant,
Lilyana Amezcua, Nancy Sicotte, Kerstin Hellwig, Lauren
Krupp, Bianca Weinstock-Guttman, Ann Yeh, Robyn M. Lucas,
Erin E. Longbrake, Vijay Yadav, Mary Rensel, Soe Mar, Carrie
Hersh, Valerie Block, Frauke Zipp, May H. Han, Rebecca
Spain, Eve E. Kelland, Leigh Charvet, Dalia Dimitri, Caroline
Papeix, Anne H. Cross, Matilde Inglese, Maria Pia Amato, Laura
Airas, Emmanuelle Leray, Maria Pia Sormani, Anneke Van der
Walt, Sandra Vukusic, Tamara Castillo-Trivino, Silvia Tenem-
baum, Olga Ciccarelli, Giulia Bommarito, Maria Petracca, Elisa-
beth Gulowsen Celius, Monica J. Carson, Le H. Hua, Ingrid
Van der Mei, Catherine Lubetzki, Vilija Jokubaitis, Maria Tro-
jano, Rhonda Voskuhl, Mar Tintore, Hanne Harbo, Nasrin
Asgari, Laura Piccio, Jodie M. Burton, Helen Tremlett, Myla
D. Goldman, Laure Michel, Yunyan Zhang, Riley Bove, Jacque-
line A. Quandt, Fiona Costello, Carolina Ionete, Christine
Lebrun-Frenay, Julia Pakpoor, Carolyn Bevan, Sarah
A. Morrow, Amy T. Waldman, Jiwon Oh, Dina Jacobs, Jacque-
line Palace, Ruth Ann Marrie, Seema K. Tiwari-Woodruff,
Luanne M. Metz, Rosa Cortese, Tanuja Chitnis, Leslie Benson,
Etty (Tika) Benveniste, Jill Conway, Ilana Katz Sand, Jennifer
Orthmann Murphy, Mariko Kita, Claire Riley, Joan
M. Goverman, Annette M. Langer-Gould, Christina J. Azevedo,
Idanis Berrios Morales, Lisa F. Barcellos, Elizabeth Crabtree,
Prue Plummer, Afsaneh Shirani, Katherine Whartenby, Fabienne
Brilot-Turville, Elaine Kingwell, Patricia Coyle, Ellen Mowry,
Rana Zabad, Bibi Bielekova, Nancy Monson, Cornelia Laule,
Margaret Burnett, Teri Schreiner, Judith Grinspan, Ruth Dob-
son, Katerina Akassoglou, Jennifer Graves, Orla Gray, Penelope
Smyth, Eva Kubala Havrdova, Jana Lizrova Preiningerova,
Brenda Banwell, Naila Makhani, Claudia Lucchinetti, Georgina
Arrambide, Elisabeth Maillart, Wendy Macklin, and Wendy
Gilmore on behalf of the International Women in MS.
The information in the letter is the opinion of the con-
signees and may not necessarily reflect a policy of their
institutions.
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A Validated Test for Neurogenic Orthostatic
Hypotension at the Bedside
Lucy Norcliffe-Kaufmann, PhD,
Jose-Alberto Palma, MD, PhD, and
Horacio Kaufmann, MD
We read with interest the small study by Balagny and colleagues,
performed in response to our publication on the orthostatic heart
rate (HR) and blood pressure (BP) changes in the diagnosis of
neurogenic orthostatic hypotension.1 Our study, which was a
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